Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by Brokerages

Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have received an average broker rating score of 1.50 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Analysts have set a twelve-month consensus target price of $15.50 for the company and are forecasting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 183 out of 265 based on the ratings given to related companies.

Several equities analysts recently commented on the stock. ValuEngine upgraded shares of Leap Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 22nd. Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Tuesday, January 23rd.

An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC acquired a new stake in Leap Therapeutics Inc (NASDAQ:LPTX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned approximately 0.72% of Leap Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 3.25% of the company’s stock.

NASDAQ:LPTX opened at $8.90 on Friday. The firm has a market cap of $141.82, a P/E ratio of -2.69 and a beta of -0.39. Leap Therapeutics has a one year low of $4.90 and a one year high of $10.01.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Friday, February 23rd. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. equities analysts predict that Leap Therapeutics will post -2.52 earnings per share for the current year.

WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply